AbClon Inc. announced that it has developed and launched ‘mRMab’, a differentiated antibody therapy platform that integrates messenger RNA (mRNA) technology with existing antibody discovery techniques.

RNA technology has emerged as a new paradigm in the medical field and has played a key role in the COVID-19 vaccine that has saved millions of lives worldwide.

The core principle of this technology is to design mRNA corresponding to a specific disease-related protein and induce an immune response in animals. When the disease protein is naturally produced in the body, the immune system recognizes it and produces antibodies specific to that protein.

Traditional antibody development methods rely on externally synthesized proteins, which often differ in structure from those naturally produced in the body. This discrepancy makes it difficult to develop antibodies for intractable diseases, often leading to failure. Additionally, the preparation of synthetic proteins requires significant time and cost.

In contrast, the mRMab approach enables the in vivo production of disease-related proteins, allowing complex protein structures to form naturally. According to AbClon, this advancement facilitates the effective development of therapeutic antibodies for proteins associated with intractable diseases that were previously difficult to target using conventional methods.

According to Global Market Insights, the global monoclonal antibody therapeutics market, a leading segment of antibody-based therapies, was valued at over USD 186.6 billion in 2022. It is expected to reach over USD 609 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.5%. Monoclonal antibody therapeutics are continuously evolving into bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies.

AbClon plans to operate a differentiated new drug platform to provide new drug development and antibody development services to pharmaceutical companies, research institutes, and hospitals worldwide.

An AbClon representative stated, " The mRMab platform is expected to bring groundbreaking innovation to therapeutic antibody development, surpassing existing methods. It will play a crucial role in developing antibody therapies for intractable diseases like cancer and new infectious diseases."